Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results

Lignende værker

• <i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
  af: Fieke W. Hoff, et al.
  Udgivet: (2025-11-01)
• P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
  af: Alice Mims, et al.
  Udgivet: (2023-08-01)
• Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
  af: Michael J. Hochman, et al.
  Udgivet: (2026-04-01)
• Beat AML genetic risk stratification model in a cohort of older VEN/HMA-treated patients with AML
  af: Fieke W. Hoff, et al.
  Udgivet: (2025-08-01)
• P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
  af: Jan Bewersdorf, et al.
  Udgivet: (2023-08-01)